OIPE ED TO

POWER OF ATTORNEY and CORRESPONDENCE ADDRESS INDICATION FORM

	71 0/3B/81 (04-03
Application Number	10/559,405
Filing Date	12/5/05
First Named Inventor	John W. Patterson
Title	AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS
Art Unit	
Examiner Name	
Attornov Docket Number	045050 005040110

İ		Examin	er Name			
	Attorney Docket Number 015		015058-0	15058-005010US		
I hereby revoke all previous powers of attorney given in the above-identified application.						
I hereby appoint:						
Practitioners a Number:	ssociated with the Customer	ted with the Customer 20350				
OR			-			
Practitioner(s)	named below:					
	Name Registration Number					
-						
as my/our attorney(s) o	r agent(s) to prosecute the application	identified abo	ove, and to transact all	business in t	the United States Pater	t and
Trademark Office conn						
	nange the correspondence address fo	r the above-i	dentified application to	o:		
The address	associated with the above-mentioned	Customer N	umber:			
OR			· · · · · · · · · · · · · · · · · · ·			
The address :	associated with Customer Number:					
OR				·		
Firm or Individual Name						
Address					. "	
	٠					
City		State Zip				
Country						
Telephone		Email				
l am the: Applicant/Inventor.						
Assignee of record of the entire interest. See 37 CFR 3.71. Statement under 37 CFR 3.73(b) is enclosed. (Form PTC/SB/96).						
Signature of Applicant or Assignee of Record						
Signature Wayse Mongonery Date 6/21/06						
Name	WAYNE MONTE	DMER	Y Tel	ephone 65	08666636	
Title and Company ASSISTANT SECRETARY Applera CARPORATION				ON		
NOTE: Signatures of all the inventors or assignees of record of the entire interest or their representative(s) are required. Submit multiple forms if more than one signature is required, see below.						
*Total of forms are submitted.						

60797361 v1



PTO/SB/98 (04-03)
Attorney Docket No. 015058-005010US

	STATER	MENERONDER 37 CFR 3.73(b)			
Applicant/Patent Ow	ner: John W. Patterson an	d Soon H. Woo			
Application Serlal No: 10/559,405 Filed/Issue Date: 12/05/05					
Entitled: AMIDINO	COMPOUNDS AS CYSTEI	NE PROTEASE INHIBITORS			
APPLERA CORPOR	RATION	a Corporation			
(Name of Assignee)	(Type of	Assignee, e.g., corporation, partnership, university, government agency, etc.)			
states that it is:					
1. X the assignee of record of the entire right, title, and interest; or					
2. an assignee of less than the entire right, title and interest. The extent (by, percentage) of its ownership interest is %					
in the patent applica	tion/patent identified above	by virtue of either:			
was recorded		e patent application/patent identified above. The assignment and Trademark Office at Reel, Frame, or for			
OR					
	from the originally named signee as shown below:	inventor(s), of the patent application/patent identified above, to			
1. From:		То :			
		United States Patent and Trademark Office at nich a copy thereof is attached.			
2. From:		To:			
		United States Patent and Trademark Office at alch a copy thereof is attached.			
3. From:		То :			
		United States Patent and Trademark Office at nich a copy thereof is attached.			
☐ Additiona	al documents in the chain o	f title are listed on a supplemental sheet.			
☐ Copies of assign	ments or other documents	in the chain of title are attached.			
[NOTE: A separa must be submitte	te copy (i.e., the original as	signment document or a true copy of the original document) n accordance with 37 CFR Part 3, if the assignment is to be			
The undersigned (wh	nose title is supplied below)	is authorized to act on behalf of the assignee.			
6	120 106	WAYNE MONTGOMERY			
	Date	Typed or printed name			
		Whepe Most sprong			
		Signature /			
		Title			
		••••			

Attorney Docket No.: 015058-005010US Client Ref. No.: CL001471 PCT-US



DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	AMIDINO COMPOUNDS AS CYSTEINE PROTEASE INHIBITORS			
Invention				
As the below	v named inventor(s), I/we declare that:			
This declara	tion is directed to:			
	The attached application, or			
	Application No. 10/559,405 , filed on December 5, 2005 , Int'l Application No.: PCT/US04/17654 International Filing Date: June 4, 2004			
	as amended on (if applicable);			
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;				
I/we have re amendment	viewed and understand the contents of the above-identified application, including the claims, as amended by any specifically referred to above;			
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.				
	WARNING:			
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.				
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.				
FULL NAM	IE OF INVENTOR(S)			
Inventor or	ne: John W. Patterson Citizen of: United States			
Signature:	John W. Pattern Date: June 8, 2006			
Inventor tw	vo: Soon H. Woo Citizen of: Canada			
Signature:	Date:			
Addition	nal inventors or a legal representative are being named onadditional form(s) attached hereto.			

Attorney Docket No.: 015058-005010US Client Ref. No.: CL001471 PCT-US

PTO/SB/01A 10-05)

DECLARATION (37 CFR 1.63) FOR UTILITY OR DESIGN APPLICATION USING AN APPLICATION DATA SHEET (37 CFR 1.76)

Title of	AMIDINO COMPOUNDS AS CYSTEINE PROTEASE IN	HIBITORS
Invention	•	
As the below	v named inventor(s), I/we declare that:	
This declara	tion is directed to:	·
	The attached application, or	
	Application No. 10/559,405, filed of Int'l Application No.: PCT/US04/17654 Internation	on <u>December 5, 2005</u> , nal Filing Date: June 4, 2004
	as amended on	(if applicable);
I/we believe that I/we am/are the original and first inventor(s) of the subject matter which is claimed and for which a patent is sought;		
	viewed and understand the contents of the above-identified applic specifically referred to above;	cation, including the claims, as amended by any
I/we acknowledge the duty to disclose to the United States Patent and Trademark Office all information known to me/us to be material to patentability as defined in 37 CFR 1.56, including for continuation-in-part applications, material information which became available between the filing date of the prior application and the national or PCT International filing date of the continuation-in-part application.		
-	WARNING:	
Petitioner/applicant is cautioned to avoid submitting personal information in documents filed in a patent application that may contribute to identity theft. Personal information such as social security numbers, bank account numbers, or credit card numbers (other than a check or credit card authorization form PTO-2038 submitted for payment purposes) is never required by the USPTO to support a petition or an application. If this type of personal information is included in documents submitted to the USPTO, petitioners/applicants should consider redacting such personal information from the documents before submitting them to the USPTO. Petitioner/applicant is advised that the record of a patent application is available to the public after publication of the application (unless a non-publication request in compliance with 37 CFR 1.213(a) is made in the application) or issuance of a patent. Furthermore, the record from an abandoned application may also be available to the public if the application is referenced in a published application or an issued patent (see 37 CFR 1.14). Checks and credit card authorization forms PTO-2038 submitted for payment purposes are not retained in the application file and therefore are not publicly available.		
All statements made herein of my/our own knowledge are true, all statements made herein on information and belief are believed to be true, and further that these statements were made with the knowledge that willful false statements and the like are punishable by fine or imprisonment, or both, under 18 U.S.C. 1001, and may jeopardize the validity of the application or any patent issuing thereon.		
FULL NAM	IE OF INVENTOR(S)	
Inventor or	ne: John W. Patterson	Citizen of: United States
Signature:		Date:
Inventor tw	ro: Soon H. Woo	Citizen of: Canada
Signature:	Soentwoo	Date: May 27, 2006
Additio	nal inventors or a legal representative are being named on	additional form(s) attached hereto.